Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 PS Ratio is 13.72 as of Aug. 11, 2026, which is 17% below its 10-year median of 16.48. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, CF PharmTech ranks worse than 90.55% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CF PharmTech's share price is HK$17.35.
CF PharmTech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.27. Hence, CF PharmTech's PS Ratio for today is 13.72.
The historical rank and industry rank for CF PharmTech's PS Ratio or its related term are showing as below:
HKSE:02652'
s PS Ratio Range Over the Past 10 Years
Min: 12.24 Med: 16.48 Max: 30.83
Current: 13.71
During the past 4 years, CF PharmTech's highest PS Ratio was 30.83. The lowest was 12.24. And the median was 16.48.
HKSE:02652's PS Ratio is ranked worse than 90.55% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.365
vs HKSE:02652: 13.71
CF PharmTech Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of CF PharmTech was -41.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.70% per year.
During the past 4 years, CF PharmTech's highest 3-Year average Revenue per Share Growth Rate was -0.70% per year. The lowest was -0.70% per year. And the median was -0.70% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CF PharmTech PS Ratio Related Terms
CF PharmTech PS Ratio Historical Data
* Premium members only.
The historical data trend for CF PharmTech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech PS Ratio Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
0.00
28.46
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
0.00
28.46
HKSE:02652 vs ZTS: PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's PS Ratio distribution charts can be found below:
* The bar in red indicates where CF PharmTech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CF PharmTech's PS Ratio for today is calculated as
CF PharmTech's Share Price of today is HK$17.35.
For company reported annually, GuruFocus uses latest annual data as the TTM data. CF PharmTech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CF PharmTech (HKSE:02652) has a PS Ratio of 13.72 as of Aug. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CF PharmTech and its competitors. This is 17% below median its historical median of 16.48. Over the past decade, CF PharmTech's PS Ratio has ranged from 12.24 to 30.83. According to the industry distribution chart, CF PharmTech ranks #862 out of 952 companies in the Drug Manufacturers industry, placing it in the top 90.5%.
Is CF PharmTech's PS Ratio too high?
CF PharmTech's current PS Ratio of 13.72 is 17% below median its 10-year median of 16.48. Over the past 10 years, this metric has ranged from a low of 12.24 to a high of 30.83. The Drug Manufacturers industry median PS Ratio is 2.37. CF PharmTech's value of 13.72 is 480.1% above this industry median. Based on the distribution chart, CF PharmTech ranks #862 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #862 out of 952 companies for PS Ratio. This places CF PharmTech in the lower half of its industry. The industry median PS Ratio is 2.37. CF PharmTech's value of 13.72 is 480.1% above this benchmark. Historically, CF PharmTech's own PS Ratio has ranged from 12.24 to 30.83 over the past decade. While the company's 10-year median is 16.48 vs. the industry median of 2.37, CF PharmTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.37, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CF PharmTech's current PS Ratio of 13.72 is 480.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current PS Ratio is 13.72, which is 17% below median its own 10-year median of 16.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current PS Ratio of 13.72. The current PS Ratio is 13.72, which is 17% below median its 10-year median of 16.48 and 480.1% above the Drug Manufacturers industry median of 2.37. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current PS Ratio is 13.72 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
